Role of genetic factors in statins side-effects

Cardiovascular and Hematological Disorders - Drug Targets

Volumn 12, Issue 1, 2012, Pages 35-43

  Scarpini, Francesca ^a   Cappellone, Roberta ^a   Auteri, Alberto ^a   Puccetti, Luca ^a  

^a UNIVERSITY OF SIENA   (Italy)

Author keywords

Myopathy; Pharmacogenetics; Side effects; SLCO1B1; Statins; Tolerability

Indexed keywords

ADENOSINE MONOPHOSPHATE DEAMINASE; ALANINE AMINOTRANSFERASE; ATORVASTATIN; CALCIUM; CERIVASTATIN; CLOFIBRIC ACID; CREATINE KINASE; CYTOCHROME P450 3A4; CYTOCHROME P450 3A5; DILTIAZEM; GEMFIBROZIL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; MEVINOLIN; PRAVASTATIN; ROSUVASTATIN; SIMVASTATIN; UBIDECARENONE; VITAMIN D;

ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALLELE; ARTICLE; CALCIUM HOMEOSTASIS; CHROMOSOME 12; COQ2 GENE; CREATINE KINASE BLOOD LEVEL; DIABETIC PATIENT; DISEASE SEVERITY; DRUG HYPERSENSITIVITY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FRAMESHIFT MUTATION; GENE; GENETIC ASSOCIATION; GENETIC VARIABILITY; GLYCOGEN STORAGE DISEASE; HEREDITY; HETEROZYGOTE; HOMOZYGOTE; HUMAN; HYPERCHOLESTEROLEMIA; LIVER TOXICITY; MALIGNANT HYPERTHERMIA; MITOCHONDRIAL MYOPATHY; MUSCULAR DYSTROPHY; MYALGIA; MYOPATHY; MYOSITIS; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PHARMACOGENETICS; PROTEIN EXPRESSION; REBOUND; RHABDOMYOLYSIS; SIDE EFFECT; SINGLE NUCLEOTIDE POLYMORPHISM; SKELETAL MUSCLE; SLCO1B1 GENE; VITAMIN METABOLISM;

ALKYL AND ARYL TRANSFERASES; FEMALE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; MUSCULAR DISEASES; ORGANIC ANION TRANSPORTERS; PHARMACOGENETICS; RISK FACTORS;

EID: 84867566124     PISSN: 1871529X     EISSN: None     Source Type: Journal    
DOI: 10.2174/187152912801823138     Document Type: Article

References (112)

1. Shepherd, J. Who should receive a statin these days? Lessons from recent clinical trials. J. Intern. Med., 2006, 260, 305-319.
2. Vandenberg B.F.; Robinson, J. Management of the Patient with Statin Intolerance. Curr. Atheroscler. Rep., 2010, 12, 48-57.
3. Armitage, J. The safety of statins in clinical practice. Lancet, 2007, 370, 1781-1790.
4. Puccetti, L.; Pasqui, A.L.; Pastorelli, M.; Bova, G.; Di Renzo, M.; Leo, A.; Cercignani, M.; Palazzuoli, A.; Auteri, A.; Bruni, F. Platelet hyperactivity after statin treatment discontinuation. Thromb. Haemost., 2003, 90, 476-482.
5. Pineda, A.; Cubeddu, L.X. Statin Rebound or Withdrawal Syndrome: Does It Exist? Curr. Atheroscler. Rep., 2011, 13, 23-30.
6. Simpson, R.J. Jr; Mendys, P. The effects of adherence and persistence on clinical outcomes in patients treated with statins: a systematic review. J. Clin. Lipidol., 2010, 4, 462-471.
7. Gotto, J.A.M. Statins, cardiovascular disease, and drug safety. Am. J. Cardiol., 2006, 97, S3-5.
8. Rossi, J.S.; McLeod, H.L. The pharmacogenetics of statin therapy: when the body aches, the mind will follow. J. Am. Coll. Cardiol., 2009, 54:1617-1618.
9. Joy, T.R.; Hegele R.A. Narrative review: statin-related myopathy. Ann. Intern. Med., 2009, 150, 858-868.
10. Sewright, K.A.; Clarkson, P.M.; Thompson, P.D. Statin myopathy: incidence, risk factors and pathophysiology. Curr. Atherosclr. Rep., 2007, 9, 389-396.
11. Thompson, P.D.; Clarkson, P.; Karas, R.H. Statin-associated myopathy. JAMA, 2003, 289, 1681-1690.
12. Jacobson, T.A. Myopathy with statin-fibrate combination therapy: clinical considerations. Nat. Rev. Endocrinol., 2009, 5, 507-518.
13. Neuvonen, P.J.; Niemi, M.; Backman, J.T. Drug interactions with lipid-lowering drugs: mechanisms and clinical relevance. Clin. Pharmacol. Ther., 2006, 80, 565-581.
14. Law, M.; Rudnicka A.R. Statin safety: a systematic review. Am J. Cardiol, 2006, 17, 97, 52C-60C.
15. Hu, M.; Mak, W.; Tomlinson, B. Simvastatin-induced myopathy, the role of interaction with diltiazem and genetic predisposition. J. Clin. Pharm. Ther., 2011, 36, 419-425.
16. Baer, A.N.; Wortmann, R.L. Myotoxicity associated with lipidlowering drugs. Curr. Opin. Rheumatol., 2007, 19, 67-73.
17. Vaklavas, C.; Chatzizisis, Y.S.; Ziakas, A.; Zamboulis, C.; Giannoglou G.D. Molecular basis of statin-associated myopathy. Atherosclerosis, 2009, 202, 18-28.
18. Harper, C.R.; Jacobson, T.A. Evidence-based management of statin myopathy. Curr. Atheroscler. Rep., 2010, 12, 322-330.
19. Lennernas, H.; Fager, G. Pharmacodynamics and pharmacokinetics of the HMGCoA reductase inhibitors. Similarities and differences. Clin. Pharmacokinet., 1997, 32, 403-425.
20. McClure, D.L.; Valuck, R.J.; Glanz, M.; Murphy, J.R.; Hokanson J.E. Statin and statin-fibrate use was significantly associated with increased myositis risk in a managed care population. J. Clin. Epidemiol., 2007, 60, 812-818.
21. Jacobson T.A. Statin safety: lessons from new drug applications for marketed statins. Am. J. Cardiol., 2006, 97, 44C-51C.
22. Pasanen, M.K.; Fredrikson, H.; Neuvonen P.J.; Niemi, M. Different effects of SLCO1B1 polymorphism on the pharmacokinetics of atorvastatin and rosuvastatin. Clin. Pharmacol. Ther., 2007, 82, 726-733.
23. Konig, J.; Seithel, A.; Gradhand, U.; Fromm, M.F. Pharmacogenomics of human OATP transporters. Naunyn Schmiedebergs Arch. Pharmacol., 2006, 372, 432-443.
24. Pasanen, M.K.; Neuvonen, M.; Neuvonen, P.J.; Niemi, M. SLCO1B1 polymorphism markedly affects the pharmacokinetics of simvastatin acid. Pharmacogenet. Genomics, 2006,16, 873-879.
25. Chen, C.; Stock, J.L.; Liu, X.; Van Deusen, J.W.; DiMattia, D.A.; Dullea, R.G.; de Morais, S.M. Utility of a novel Oatp1b2 knockout mouse model for evaluating the role of Oatp1b2 in the hepatic uptake of model compounds. Drug. Metab. Dispos., 2008, 36, 1840-1845.
26. Niemi, M.; Pasanen, M.K.; Neuvonen, P.J.; SLCO1B1 polymorphism and sex affect the pharmacokinetics of pravastatin but not fluvastatin. Clin. Pharmacol. Ther., 2006, 80, 356-366.
27. Niemi, M.; Schaeffeler, E.; Lang, T.; Fromm, M.F.; Neuvonen, M.; Kyrklund, C.; Backman, J.T.; Kerb, R.; Schwab, M.; Neuvonen, P.J.; Eichelbaum, M.; Kivistö, K.T. High plasma pravastatin concentrations are associated with single nucleotide polymorphisms and haplotypes of organic anion transporting polypeptide-C (OATP-C, SLCO1B1). Pharmacogenetics, 2004, 14, 429-440.
28. Morimoto, K.; Oishi, T.; Ueda, S.; Ueda, M.; Hosokawa, M.; Chiba, K. A novel variant allele of OATP-C (SLCO1B1) found in a Japanese patient with pravastatin-induced myopathy. Drug. Metab. Pharmacokinet., 2004, 19, 453-355.
29. Kameyama, Y.; Yamashita K.; Kobayashi, K.; Hosokawa, M.; Chiba, K. Functional characterization of SLCO1B1 (OATP-C) variants, SLCO1B1*5, SLCO1B1*15 and SLCO1B1*15+C1007G, by using transient expression systems of HeLa and HEK293 cells. Pharmacogenet. Genomics, 2005, 15, 513-522.
30. SEARCH Collaborative Group; Link, E.; Parish, S.; Armitage, J.; Bowman, L.; Heath, S.; Matsuda, F.; Gut, I.; Lathrop, M.; Collins, R. SLCO1B1 variants and statin-induced myopathy - a genomewide study. N. Engl. J. Med., 2008, 359, 789-799.
31. Voora, D.; Shah, S.H.; Spasojevic, I.; Ali, S.; Reed, C.R.; Salisbury, A.; Ginsburg, G.S. The SLCO1B1*5 genetic variant is associated with statin-induced side effects. J. Am. Coll. Cardiol., 2009, 54, 1609-1616.
32. Donnelly, L.A.; Doney, A.S.; Tavendale, R.; Lang, C.C.; Pearson, E.R.; Colhoun, H.M.; McCarthy, M.I.; Hattersley, A.T.; Morris, A.D.; Palmer, C.N. Common nonsynonymous substitutions in SLCO1B1 predispose to statin intolerance in routinely treated individuals with type 2 diabetes: a go-DARTS study. Clin. Pharmacol. Ther., 2011, 89, 210-216.
33. Brunham, L.R.; Lansberg, P.J.; Zhang, L.; Miao, F.; Carter, C.; Hovingh, G.K.; Visscher, H.; Jukema, J.W.; Stalenhoef, A.F.; Ross, C.J.; Carleton, B.C.; Kastelein, J.J.; Hayden, M.R. Differential effect of the rs4149056 variant in SLCO1B1 on myopathy associated with simvastatin and atorvastatin. Pharmacogenomics, J., 2011 doi:10.1038/tpj.2010.92.
34. Butler, M.A.; Lang, N.P.; Young, J.F.; Caporaso, N.E.; Vineis, P.; Hayes, R.B.; Teitel, C.H.; Massengill, J.P.; Lawsen, M.F.; Kadlubar, F.F. Determination of CYP1A2 and NAT2 phenotypes in human populations by analysis of caffeine urinary metabolites. Pharmacogenetics, 1992, 2, 116-127.
35. Williams D, Feely J. Pharmacokinetic-pharmacodynamic drug interactions with HMG-CoA reductase inhibitors. Clin. Pharmacokinet., 2002, 41, 343-370.
36. Nordin C, Dahl ML, Eriksson M, Sjoberg S. Is the cholesterollowering effect of simvastatin influenced by CYP2D6 polymorphism? Lancet, 1997, 350, 29-30.
37. Marez, D.; Legrand, M.; Sabbagh, N.; Lo Giudice J.M.; Spire, C.; Lafitte J.J.; Meyer, U.A.; Broly, F. Polymorphism of the cytochrome P450 CYP2D6 gene in a European population: characterization of 48 mutations and 53 alleles, their frequencies and evolution. Pharmacogenetics, 1997, 7, 193-202.
38. Johansson, I.; Lundqvist, E.; Bertilsson, L.; Dahl, M.L.; Sjöqvist, F.; Ingelman-Sundberg M. Inherited amplification of an active gene in the cytochrome P450 CYP2D locus as a cause of ultrarapid metabolism of debrisoquine. Proc. Natl. Acad. Sci. USA, 1993, 90, 11825-11829.
39. Dahl, M.L.; Johansson, I.; Bertilsson, L.; Ingelman-Sundberg, M.; Sjoqvist F. Ultrarapid hydroxylation of debrisoquine in a Swedish population. Analysis of the molecular genetic basis. J. Pharmacol. Exp. Ther., 1995, 274, 516-520.
40. Mulder, A.B.; van Lijf, H.J.; Bon, M.A.; van den Bergh, F.A.; Touw, D.J.; Neef, C.; Vermes, I. Association of polymorphism in the cytochrome CYP2D6 and the efficacy and tolerability of simvastatin. Clin. Pharmacol. Ther., 2001, 70, 546-551.
41. Kim, K.; Johnson, J.A.; Derendorf, H. Differences in drug pharmacokinetics between East Asians and Caucasians and the role of genetic polymorphisms. J. Clin. Pharmacol., 2004, 44, 1083-1105.
42. Zuccaio, P.; Mombelli, G.; Calabresi, L.; Baldassarre, D.; Palmi, I.; Sirtori C.R. Tolerability of statins is not linked to CYP450 polymorphisms, but reduced CYP2D6 metabolism improves cholesterolemic response to simvastatin and fluvastatin. Pharmacol. Res., 2007, 55, 310-317.
43. Pasternak, R.C.; Smith, S.C.; Bairey-Merz, C.N.; Grundy, S.M.; Cleeman, J.I.; Lenfant, C. American College of Cardiology; American Heart Association; National Heart, Lung and Blood Institute. ACC/AHA/NHLBI clinical advisory on the use and safety of statins. J. Am. Coll. Cardiol., 2002, 40, 567-572.
44. Frudakis, T.N.; Thomas, M.J.; Ginjupalli, S.N.; Handelin, B.; Gomez, H.J. CYP2D6*4 polymorphism is associated with statin-induced muscle effects. Pharmacogenetic. Genomics, 2007, 17, 695-707.
45. Bullen, W.W.; Miller, R.A.; Hayes, R.N. Development and validation of a highperformance liquid chromatography tandem mass spectrometry assay for atorvastatin, ortho-hydroxy atorvastatin, and para-hydroxy atorvastatin in human, dog, and rat plasma. J. Am. Soc. Mass. Spectrom., 1999, 10, 55-66.
46. Wilke, R.A.; Moore, J.H.; Burmester, J.K. Relative impact of CYP3A genotype and concomitant medication on the severity of atorvastatin-induced muscle damage. Pharmacogenet. Genomics, 2005, 15, 415-421.
47. Ishikawa, C.; Ozaki, H.; Nakajima, T.; Ishii, T.; Kanai, S.; Anjo, S.; Shirai, K.; Inoue, I. A frameshift variant of CYP2C8 was identified in a patient who suffered from rhabdomyolysis after administration of cerivastatin. J. Hum. Genet, 2004, 49, 582-585.
48. Transon, C.; Leemann, T.; Dayer, P. In vitro comparative inhibition profiles of major human drug metabolising cytochrome P450 isozymes (CYP2C9, CYP2D6 and CYP3A4) by HMG-CoA reductase inhibitors. Eur. J. Clin. Pharmacol., 1996, 50, 209-215.
49. Carswell, C.I.; Plosker, G.L.; Jarvis, B. Rosuvastatin. Drugs, 2002, 62, 2075-2085.
50. Bolego, C.; Poli, A.; Cignarella, A.; Catalano, A.L.; Paoletti, R. Novel statins: pharmacological and clinical results. Cardiovasc. Drugs. Ther., 2002, 16, 251-257.
51. Fiegenbaum, M.; da Silveira, F.R.; Van der Sand, C.R.; Van der Sand, L.C.; Ferreira, M.E.; Pires, R.C.; Hutz, M.H. The role of common variants of ABCB1, CYP3A4, and CYP3A5 genes in lipid-lowering efficacy and safety of simvastatin treatment. Clin. Pharmacol. Ther., 2005, 78, 551-558.
52. Dorajo, R. Pereira, B.P.; Yu, Z.; Gopalakrishnakone, P.; Leong, C.C.; Wee, A. Lee E. Role of multi-drug resistance-associated protein -1 transporter in statin-induced myopathy. Life Sci., 2008, 82, 823-830.
53. Guijarro, C.; Blanco-Colio L.M.; Ortego, M.; Alonso, C.; Ortiz, A.; Plaza, J.J.; Díaz, C.; Hernández, G.; Egido, J. 3-Hydroxy-3- methylglutaryl coenzyme a reductase and isoprenylation inhibitors induce apoptosis of vascular smooth muscle cells in culture. Circ. Res., 1998, 83, 490-500.
54. Ruano, G.; Thompson, P.D.; Windemuth, A.; Smith, A.; Kocherla, M.; Holford, T.R.; Seip, R.; Wu, A.H. Physiogenomic analysis links serum creatine kinase activities during statin therapy to vascular smooth muscle homeostasis. Pharmacogenomics, 2005, 6, 865-872.
55. Heydemann, A.; McNally, E. No more muscle fatigue. J. Clin. Invest., 2009, 119, 448-450.
56. Marcoff, L.; Thompson, P.D. The role of coenzyme Q10 in statinassociated myopathy: a systematic review. J. Am. Coll. Cardiol., 2007, 49, 2231-2237.
57. Quinzii, C.; Naini, A.; Salviati, L.; Trevisson, E.; Navas, P.; Dimauro, S.; Hirano M.A. mutation in para-hydroxybenzoatepolyprenyl transferase (COQ2) causes primary coenzyme Q10 deficiency. Am. J. Hum. Genet, 2006, 78, 345-349.
58. Oh, J.; Ban, M.R.; Miskie, B.A.; Pollex, R.L.; Hegele, R.A. Genetic determinants of statin intolerance. Lipids Health Dis., 2007, doi:10.1186/1476-511X-6-7.
59. Puccetti, L.; Ciani, F.; Auteri, A. Genetic involvement in statins induced myopathy. Preliminary data from an observational casecontrol study. Atherosclerosis, 2010, 211, 28-29.
60. Inoue, R.; Tanabe, M.; Kono, K.; Maruyama, K.; Ikemoto, T.; Endo, M. Ca(2+)-releasing effect of cerivastatin on the sarcoplasmic reticulum of mouse and rat skeletal muscle fibers. J. Pharmacol. Sci., 2003, 93, 279-288.
61. Nakahara, K.; Yada, T.; Kuriyama, M.; Osame, M. Cytosolic Ca2+ increase and cell damage in L6 rat myoblasts by HMG-CoA reductase inhibitors. Biochem. Biophys. Res. Commun., 1994, 202, 1579-1585.
62. Ikemoto, T. Endo, M. Properties of Ca(2+) release induced by clofibric acid from the sarcoplasmic reticulum of mouse skeletal muscle fibres. Br. J. Pharmacol., 2001, 134, 719-728.
63. Gray, D.F.; Bundgaard, H.; Hansen, P.S.; Buhagiar, K.A.; Mihailidou, A.S.; Jessup, W.; Kjeldsen, K.; Rasmussen, H.H. HMG-CoA-reductase inhibition reduces sarcolemmal Na(+)-K(+) pump density. Cardiovasc. Res., 2000, 47, 329-335.
64. Baker, S.K.; Tarnopolsky, M.A. Statin myopathies: pathophysiologic and clinical perspectives. Clin. Invest. Med., 2001, 24, 258-272.
65. Mosieniak, G.; Figiel, I.; Kaminska, B. Cyclosporin A, an immunosuppressive drug, induces programmed cell death in rat C6 glioma cells by a mechanism that involves the AP-1 transcription factor. J. Neurochem., 1997, 68, 1142-1149.
66. Gupta, A.; Thompson, P.D. The relationship of vitamin D deficiency to statin myopathy. Atherosclerosis, 2011, 215, 23-29.
67. Ahmed, W.; Khan, N.; Glueck, C.J.; Pandey, S.; Wang, P.; Goldenberg, N.; Uppal, M.; Khanal, S. Low serum 25 (OH) vitamin D levels (<32 ng/mL) are associated with reversible myositismyalgia in statin-treated patients. Transl. Res., 2009, 153, 11-16.
68. Duell, P.B.; Connor, W.E. Abstract 3701: vitamin D deficiency is associated with myalgias in hyperlipidemic subjects taking statins. Circulation, 2008, 118, S470.
69. Bittner, V.; Wenger, N.K.; Waters, D.D. Vitamin D levels are not related to myalgias in statin-treated patients with stable coronary disease. J. Am. Coll. Cardiol., 2010, 55, A177.E1659.
70. Linde, R.; Peng, L.; Desai, M.; Feldman, D. The role of vitamin D and SLCO1B1*5 gene polymorphism in statin-associated myalgias. Dermatoendocrinol., 2010, 2, 77-84.
71. Koeppe, C.; Schneider, C.; Thieme, K.; Mense, S.; Stratz, T.; Müller, W.; Flor, H. The influence of the 5-HT3 receptor antagonist tropisetron on pain in fibromyalgia: a functional magnetic resonance imaging pilot study. Scand. J. Rheumatol. Suppl., 2004, 119, 24-27.
72. Ruano, G.; Thompson P.D.; Windemuth, A.; Seip, R.L.; Dande, A.; Sorokin, A.; Kocherla, M.; Smith, A.; Holford, T.R.; Wu, A.H. Physiogenomic association of statin-related myalgia to serotonin receptors. Muscle. Nerve., 2007, 36, 329-335.
73. Ghatak, A.; Faheem, O.; Thompson, P.D. The genetics of statininduced myopathy. Atherosclerosis, 2010, 210, 337-343.
74. Lorenzoni, P.J.; Silvano, C.E.; Scola, R.H.; Luvizotto, M:; Werneck, L.C. McArdle disease with rhabdomyolysis induced by rosuvastatin: case report. Arq. Neuropsiquiatr., 2007, 65, 834-837.
75. Livingstone, C.; Al Riyami, S.; Wilkins, P.; Ferns, G.A. McArdle's disease diagnosed following statin-induced myositis. Ann. Clin. Biochem., 2004, 41, 338-340.
76. Barth, J.H.; Brownjohn, A.M.; Jamieson, D.R. The case of stainless statins. Ann. Clin. Biochem., 2003, 40, 576-577.
77. Vladutiu, G.D.; Simmons, Z.; Isackson, P.J.; Tarnopolsky, M.; Peltier, W.L.; Barboi, A.C.; Sripathi, N.; Wortmann, R.L.; Phillips, P.S. Genetic risk factors associated with lipid-lowering druginduced myopathies. Muscle. Nerve., 2006, 34, 153-162.
78. Barth, J.H.; Brownjohn, A.M.; Jamieson, D.R. The case of stainless statins. Ann. Clin. Biochem., 2003, 40, 576-577.
79. Voermans, N.C.; Lammens, M.; Wevers, R.A.; Hermus, A.R.; van Engelen, B.G. Statin disclosed acid maltase deficiency. J. Intern. Med., 2005, 258, 196-197.
80. Corti, S.; Bordoni, A.; Ronchi, D.; Musumeci, O.; Aguennouz, M.; Toscano, A.; Lamperti, C.; Bresolin, N.; Comi, G.P. Clinical features and new molecular findings in Carnitine Palmitoyltransferase II (CPT II) deficiency. J. Neurol. Sci., 2008, 266, 97-103.
81. Bonnefont, J.P.; Djouadi, F.; Prip-Buus, C.; Gobin, S.; Munnich, A.; Bastin, J. Carnitine palmitoyltransferases 1 and 2: biochemical, molecular and medical aspects. Mol. Aspects. Med., 2004, 25, 495-520.
82. Bhuiyan, J.; Seccombe, D.W. The effects of 3-hydroxy-3-ethylglutaryl-CoA reductase inhibition on tissue levels of carnitine and carnitine acyltransferase activity in the rabbit. Lipids, 1996, 31, 867-870.
83. Verzijl, H.T.; van Engelen, B.G.; Luyten, J.A.; Steenbergen, G.C.; van den Heuvel, L.P.; ter Laak, H.J.; Padberg, G.W.; Wevers, R.A. Genetic characteristics of myoadenylate deaminase deficiency. Ann. Neurol., 1998, 44, 140-143.
84. Morisaki, T.; Gross, M.; Morisaki, H.; Pongratz, D.; Zöllner, N.; Holmes, E.W. Molecular basis of AMP deaminase deficiency in skeletal muscle. Proc. Natl. Acad. Sci. USA, 1992, 89, 6457-6461.
85. Tarnopolsky, M.A.; Parise, G.; Gibala, M.J.; Graham, T.E.; Rush J.W. Myoadenylatedeaminase deficiency does not affect muscle anaplerosis during exhaustive exercise in humans. J. Physiol., 2001, 533, 881-889.
86. Goto, Y.; Nonaka, I.; Horai, S. A mutation in the tRNA(Leu) (UUR) gene associated with the MELAS subgroup of mitochondrial encephalomyopathies. Nature, 1990, 348, 651-653.
87. Goto, Y.; Nonaka, I.; Horai, S. A new mtDNA mutation associated with mitochondrial myopathy, encephalopathy, lactic acidosis and stroke-like episodes (MELAS). Biochim. Biophys. Ata., 1991, 1097, 238-240.
88. Nishino, I.; Komatsu, M.; Kodama, S.; Horai, S.; Nonaka, I.; Goto, Y. The 3260 mutation in mitochondrial DNA can cause mitochondrial myopathy, encephalopathy, lactic acidosis, and strokelike episodes (MELAS). Muscle. Nerve., 1996, 19, 1603-1604.
89. Blake, J.C.; Taanman, J.W.; Morris, A.M.; Gray, R.G.; Cooper, J.M.; McKiernan, P.J.; Leonard, J.V.; Schapira, A.H. Mitochondrial DNA depletion syndrome is expressed in amniotic fluid cell cultures. Am. J. Pathol., 1999, 155, 67-70.
90. Thomas, J.E.; Lee, N.; Thompson, P.D. Statins provoking MELAS syndrome. A case report. Eur. Neurol., 2007, 57, 232-235.
91. Chariot, P.; Abadia, R.; Agnus, D.; Danan, C.; Charpentier, C.; Gherardi, R.K. Simvastatin-induced rhabdomyolysis followed by a MELAS syndrome. Am. J. Med., 1993, 94, 109-110.
92. Tay, S.K.; DiMauro S.; Pang, A.Y.; Lai, P.S.; Yap, H.K. Myotoxicity of lipid-lowering agents in a teenager with MELAS mutation. Pediatr. Neurol., 2008, 39, 426-428.
93. Schick, B.A.; Laaksonen, R.; Frohlich, J.J.; Päivä, H.; Lehtimäki, T.; Humphries, K.H.; Côté, H.C. Decreased skeletal muscle mitochondrial DNA in patients treated with high-dose simvastatin. Clin. Pharmacol. Ther., 2007, 81, 650-653.
94. Paiva, H.; Thelen, K.M.; Van Coster, R.; Smet, J.; De Paepe, B.; Mattila, K.M.; Laakso, J.; Lehtimäki, T.; von Bergmann, K.; Lütjohann, D.; Laaksonen, R. High-dose statins and skeletal muscle metabolism in humans: a randomized, controlled trial. Clin. Pharmacol. Ther., 2005, 78, 60-68.
95. Phillips, P.S.; Haas, R.H.; Bannykh, S.; Hathaway, S.; Gray, N.L.; Kimura, B.J.; Vladutiu, G.D.; England, J.D. Statin-associated myopathy with normal creatine kinase levels. Ann. Intern. Med., 2002, 137, 581-585.
96. Amato, A.A.; Griggs, R.C. Overview of the muscular dystrophies. Handb. Clin. Neurol., 2011, 101, 1-9.
97. Sailler, L.; Pereira, C.; Bagheri, A.; Uro-Coste, E.; Roussel, B.; Adoue, D.; Fournie, B.; Laroche, M.; Zabraniecki, L.; Cintas, P.; Arlet, P.; Lapeyre-Mestre, M.; Montastruc, J.L. Increased exposure to statins in patients developing chronic muscle diseases: a 2-year retrospective study. Ann. Rheum. Dis., 2008, 67, 614-619.
98. Lehmann-Horn, F.; Jurkat-Rott, K.; Rüdel, R. Diagnostics and therapy of muscle channelopathies-Guidelines of the Ulm Muscle Centre. Acta. Myol., 2008, 27, 98-113.
99. Gillard, E.F.; Otsu, K.; Fujii, J.; Duff, C.; de Leon, S.; Khanna, V.K.; Britt, B.A.; Worton, R.G.; MacLennan, D.H. A substitution of cysteine for arginine 614 in the ryanodine receptor is potentially causative of human malignant hyperthermia. Genomics, 1991, 11, 751-755.
100. Monnier, N.; Procaccio, V.; Stieglitz, P.; Lunardi, J. Malignanthyperthermia susceptibility is associated with a mutation of the alpha 1-subunit of the human dihydropyridine-sensitive L-type voltage-dependent calcium-channel receptor in skeletal muscle. Am. J. Hum. Genet., 1997, 60, 1316-1325.
101. Urwyler, A.; Deufel, T.; McCarthy T.; West, S. Guidelines for molecular genetic detection of susceptibility to malignant hyperthermia. Br. J. Anaesth., 2001, 86, 283-287.
102. Guis, S.; Figarella-Branger, D.; Mattei, J.P.; Nicoli, F.; Le Fur, Y.; Kozak-Ribbens, G.; Pellissier, J.F.; Cozzone, P.J.; Amabile, N.; Bendahan, D. In vivo and in vitro characterization of skeletal muscle metabolism in patients with statin-induced adverse effects. Arthritis. Rheum., 2006, 55, 551-557.
103. Krivosic-Horber, R.; Depret, T.; Wagner, J.M.; Maurage, C.A. Malignant hyperthermia susceptibility revealed by increased serum creatine kinase concentrations during statin treatment. Eur. J. Anaesthesiol., 2004, 21, 572-574.
104. Torbergsen, T. Rippling muscle disease: a review. Muscle. Nerve., 2002, Suppl 11, S103-S107.
105. Kubisch, C.; Ketelsen, U.P.; Goebel, I.; Omran, H.; Autosomal recessive rippling muscle disease with homozygous CAV3 mutations. Ann. Neurol., 2005, 57, 303-304.
106. Ansevin, C.F.; Agamanolis, D.P. Rippling muscles and myasthenia gravis with rippling muscles. Arch. Neurol., 1996, 53, 197-199.
107. Minetti, C.; Sotgia, F.; Bruno, C.; Scartezzini, P.; Broda, P.; Bado, M.; Masetti, E.; Mazzocco, M.; Egeo, A.; Donati, M.A.; Volonte, D.; Galbiati, F.; Cordone, G.; Bricarelli, F.D.; Lisanti, M.P.; Zara, F. Mutations in the caveolin-3 gene cause autosomal dominant limb-girdle muscular dystrophy. Nat. Genet., 1998, 18, 365-368.
108. Stephan, D.A.; Hoffman, E.P. Physical mapping of the rippling muscle disease locus. Genomics, 1999, 55, 268-274.
109. Baker, S.K.; Tarnopolsky, M.A. Sporadic rippling muscle disease unmasked by simvastatin. Muscle. Nerve., 2006, 34, 478-481.
110. Romaine, S.P.; Bailey, K.M.; Hall, A.S.; Balmforth, A.J. The influence of SLCO1B1 (OATP1B1) gene polymorphisms on response to statin therapy. Pharmacogenomics. J., 2010, 10, 1-11.
111. Ruano, G.; Windemuth, A.; Wuc, A.H.B; Kaned, J.P.; Malloyd, M.J.; Pullingerd, C.R.; Kocherlab, M.; Bogaardb, K.; Gordone, B.R.; Holfordf, T.H.; Guptag, A.; Seipa, R.L.; Thompson, P.D. Mechanisms of statin-induced myalgia assessed by physiogenomic associations. Atherosclerosis, 2011, doi:10.1016/j.atherosclerosis. 2011.07.007.
112. Peters, B.J.; Klungel, O.H.; Visseren, F.L.; de Boer, A.; Maitlandvan der Zee, A.H. Pharmacogenomic insights into treatment and management of statin-induced myopathy. Genome. Med., 2009, 29, 120.